General description
The complement (C1q) and FcγR I binding sites of the Fcγ2a fragment allow the Fc portion of the fusion protein to effectively facilitate direct antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).
Biochem/physiol Actions
CD152 (CTLA4), a cell surface glycoprotein expressed at low levels on activated T cells, is a high affinity receptor for the costimulatory molecules CD80 (B7-1) and CD86 (B7-2). A related cell surface glycoprotein, CD28, binds to CD80 and CD86 with lower affinity. The soluble CD152/Fc chimeric fusion protein blocks the B7/CD28 signaling pathway by binding to CD80 and CD86.
Physical form
Solution, 0.2 μm filtered, in phosphate buffered saline, pH 7.4, with no preservative added.
Preparation Note
Purified from serum-free tissue culture supernatant
Other Notes
The extracellular domain (160 amino acids) of mouse CD152 is fused to mouse IgG2a Fc domain.
| biological source | mouse |
| Quality Segment | 200 |
| recombinant | expressed in NS.1 cells |
| assay | ≥99% (SDS-PAGE) |
| form | buffered aqueous solution |
| mol wt | 97 kDa |
| packaging | pkg of 1 mg |
| storage condition | avoid repeated freeze/thaw cycles |
| impurities | ≤1 EU/mg protein Endotoxin level (LAL test) |
| UniProt accession no. | P09793 |
| shipped in | wet ice |
| storage temp. | −20°C |
| Gene Information | mouse ... Cd152(12477), Ctla4(12477) |
